Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Therapeutics Invited to Participate in 2006 Gordon Research Conference on Peptides

SAN DIEGO, CA July 5, 2005/BusinessWire/– Aegis Therapeutics, a leader in intranasal and transmucosal delivery of peptide, protein and non-protein macromolecular drugs, today announced that Edward T. Maggio, Ph.D., President and Chief Executive Officer, will present research data on Aegis’ patented Intravail™ intranasal and transmucosal drug delivery technology at the Drug Delivery session of the 2006 Gordon Research Conference on Peptides.

According to the Mission Statement, “the Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies”. The conference, officially entitled: “Peptides: Chemistry and Biology Of” will present the most recent advances in the field of peptides and peptide-related science.  The conference will take place during the week of Feb. 19-24 2006 at the Ventura Beach Marriott, Ventura, CA.

 About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail™ drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail™ absorption enhancement agents are mild and non-irritating to mucosal membranes.  They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes.  Intravail™ also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and “first pass effect” elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: htpp://www.aegisthera.com.